Immunostimulatory colloidal delivery systems for cancer vaccines

Cancer vaccine delivery is a multidisciplinary scientific field that is currently undergoing rapid development. An important component of cancer vaccines is the development of novel vaccine delivery strategies, such as colloidal immunostimulatory delivery systems. The importance of formulation strategies for cancer vaccines can be explained by the poor immunogenicity of tumour antigens. Colloidal vaccine delivery systems modify the kinetics, body distribution, uptake and release of the vaccine. This review explores recent research that is directed towards more targeted treatments of cancer through to colloidal vaccine delivery systems. Widely investigated carrier systems include polymeric micro- and nanoparticles, liposomes, archaeal lipid liposomes (archaeosomes), immune-stimulating complexes and virus-like particles. These systems are evaluated in terms of their formulation techniques, immunological mechanisms of action as well as the potential and limitations of such colloidal systems in the field of cancer vaccines.

[1]  Sven Frokjaer,et al.  Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. , 2005, International journal of pharmaceutics.

[2]  Bror Morein,et al.  Current status and potential application of ISCOMs in veterinary medicine. , 2004, Advanced drug delivery reviews.

[3]  A. Halpern,et al.  Melanoma-associated expression of transforming growth factor-beta isoforms. , 1996, The American journal of pathology.

[4]  Sanyog Jain,et al.  Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study. , 2005, International journal of pharmaceutics.

[5]  K. Mergener,et al.  Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase. , 1993, Virology.

[6]  Manmohan J. Singh,et al.  An investigation of the factors controlling the adsorption of protein antigens to anionic PLG microparticles. , 2005, Journal of pharmaceutical sciences.

[7]  D. Swenson,et al.  Induction of Humoral and CD8+ T Cell Responses Are Required for Protection against Lethal Ebola Virus Infection1 , 2005, The Journal of Immunology.

[8]  N. Goto,et al.  Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines. , 1993, Vaccine.

[9]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[10]  R. Offringa,et al.  Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. , 1996, Journal of immunology.

[11]  R. Müller,et al.  Correlation of the surface hydrophobicity of 14C-poly(methyl methacrylate) nanoparticles to their body distribution , 1992 .

[12]  A. Gliozzi,et al.  Vesicles from mixtures of bipolar archaebacterial lipids with egg phosphatidylcholine , 1983 .

[13]  S. Steinberg,et al.  Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma , 2005, The Journal of Immunology.

[14]  G. Prud’homme.  DNA vaccination against tumors , 2005, The journal of gene medicine.

[15]  G. Boltz‐Nitulescu,et al.  Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[16]  A. Verma,et al.  Effect of molecular weight heterogeneity on drug encapsulation efficiency of gelatin nano-particles. , 2005, Colloids and surfaces. B, Biointerfaces.

[17]  E. B. Lindblad.  Aluminium compounds for use in vaccines , 2004, Immunology and cell biology.

[18]  C. Dubuquoy,et al.  TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. , 2005, Vaccine.

[19]  Wenlei Jiang,et al.  Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. , 2005, Advanced drug delivery reviews.

[20]  Tejraj M Aminabhavi,et al.  Recent advances on chitosan-based micro- and nanoparticles in drug delivery. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[21]  John Samuel,et al.  Analysis of Poly(D,L-Lactic-Co-Glycolic Acid) Nanosphere Uptake by Human Dendritic Cells and Macrophages In Vitro , 2002, Pharmaceutical Research.

[22]  P. McCue,et al.  Interleukin 10 production by human melanoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  T. Luft,et al.  ISCOM based vaccines for cancer immunotherapy. , 2004, Vaccine.

[24]  Kozo Takayama,et al.  Novel Chitosan Particles and Chitosan-Coated Emulsions Inducing Immune Response via Intranasal Vaccine Delivery , 2004, Pharmaceutical Research.

[25]  B. Rouse,et al.  Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro , 1992, The Journal of experimental medicine.

[26]  P. Ellis,et al.  Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Mark Shackleton,et al.  Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Rades,et al.  Using different structure types of microemulsions for the preparation of poly(alkylcyanoacrylate) nanoparticles by interfacial polymerization. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[29]  Circe Mesa,et al.  Challenges facing adjuvants for cancer immunotherapy , 2004, Immunology and cell biology.

[30]  Lei Zhang,et al.  Enhancement of the effectiveness of electroporation-augmented cutaneous DNA vaccination by a particulate adjuvant. , 2004, Bioelectrochemistry.

[31]  L. Brannon-Peppas,et al.  Nanoparticle and targeted systems for cancer therapy. , 2004, Advanced drug delivery reviews.

[32]  Jean M. J. Fréchet,et al.  A macromolecular delivery vehicle for protein-based vaccines: Acid-degradable protein-loaded microgels , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Coffman,et al.  T Regulatory Cells 1 Inhibit a Th2-Specific Response In Vivo1 , 2000, The Journal of Immunology.

[34]  M. L. Mackichan,et al.  Recent developments in adjuvants for vaccines against infectious diseases. , 2001, Biomolecular engineering.

[35]  T. Rades,et al.  A comparison of pseudo‐ternary diagrams of aqueous mixtures of Quil A, cholesterol and phospholipid prepared by lipid‐film hydration and dialysis , 2004, The Journal of pharmacy and pharmacology.

[36]  U. Ramstedt,et al.  Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome P450 1B1. , 2004, Clinical immunology.

[37]  P. Lenz,et al.  Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. , 2003, Clinical immunology.

[38]  N. Petrovsky,et al.  Vaccine adjuvants: Current state and future trends , 2004, Immunology and cell biology.

[39]  D. Papahadjopoulos,et al.  Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.

[40]  Shaobing Zhou,et al.  Poly-D,L-lactide-co-poly(ethylene glycol) microspheres as potential vaccine delivery systems. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[41]  J. Wilschut,et al.  Delivery of Protein Antigens to the Immune System by Fusion-Active Virosomes: A Comparison with Liposomes and ISCOMs , 2002, Bioscience reports.

[42]  T. Rades,et al.  Incorporation of ovalbumin into ISCOMs and related colloidal particles prepared by the lipid film hydration method. , 2004, International journal of pharmaceutics.

[43]  S. Standley,et al.  Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles , 2005, Journal of Controlled Release.

[44]  M. Pizza,et al.  Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. , 2004, Journal of pharmaceutical sciences.

[45]  G. Sprott,et al.  Archaeobacterial ether lipid liposomes as vaccine adjuvants. , 2003, Methods in enzymology.

[46]  J. Andersson,et al.  Immune complement activation on polystyrene and silicon dioxide surfaces. Impact of reversible IgG adsorption. , 2005, Molecular immunology.

[47]  H. Junginger,et al.  Preparation of coated nanoparticles for a new mucosal vaccine delivery system. , 2005, International journal of pharmaceutics.

[48]  S. Davis,et al.  Chitosan as a novel nasal delivery system for vaccines. , 2001, Advanced drug delivery reviews.

[49]  C. Choquet,et al.  Stability of pressure-extruded liposomes made from archaeobacterial ether lipids , 1994, Applied Microbiology and Biotechnology.

[50]  E. B. Lindblad.  Aluminium adjuvants--in retrospect and prospect. , 2004, Vaccine.

[51]  A. Osterhaus,et al.  Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses , 1984, Nature.

[52]  M. C. Popescu,et al.  Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma Antigen , 2004, Clinical Cancer Research.

[53]  J. Viret,et al.  Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. , 2004, Current opinion in biotechnology.

[54]  S. Croft,et al.  Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs , 2003, Parasitology Research.

[55]  H. Kodama,et al.  Protection against experimental Aeromonas salmonicida infection in carp by oral immunisation with bacterial antigen entrapped liposomes. , 2005, Fish & shellfish immunology.

[56]  A. Sher,et al.  Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. , 1997, Journal of immunology.

[57]  P. G. Seferian,et al.  Immune stimulating activity of two new chitosan containing adjuvant formulations. , 2000, Vaccine.

[58]  G. Patel,et al.  Archaeosomes as novel antigen delivery systems. , 1997, FEMS microbiology letters.

[59]  M. Suckow,et al.  In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. , 1997, Vaccine.

[60]  H. Morii,et al.  Special methods for the analysis of ether lipid structure and metabolism in archaea. , 2006, Analytical biochemistry.

[61]  T. Rades,et al.  Quil A-lipid powder formulations releasing ISCOMs and related colloidal structures upon hydration. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[62]  F. Authier,et al.  Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. , 2001, Brain : a journal of neurology.

[63]  Jeffrey B Ulmer,et al.  Targeting the innate immune response with improved vaccine adjuvants , 2005, Nature Medicine.

[64]  J. Clegg,et al.  Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. , 1997, Vaccine.

[65]  F. Authier,et al.  Aluminum inclusion macrophagic myofasciitis: a recently identified condition. , 2003, Immunology and allergy clinics of North America.

[66]  B. Granum,et al.  Fine particles of widely different composition have an adjuvant effect on the production of allergen-specific antibodies. , 2001, Toxicology letters.

[67]  M. Estes,et al.  Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs). , 2006, Vaccine.

[68]  D. Crommelin,et al.  Liposomes Containing Interferon-Gamma as Adjuvant in Tumor Cell Vaccines , 2004, Pharmaceutical Research.

[69]  F Ambrosch,et al.  Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. , 1997, Vaccine.

[70]  G. Patel,et al.  Archaeosome Vaccine Adjuvants Induce Strong Humoral, Cell-Mediated, and Memory Responses: Comparison to Conventional Liposomes and Alum , 2000, Infection and Immunity.

[71]  A. Houghton,et al.  Immune recognition of self in immunity against cancer. , 2004, The Journal of clinical investigation.

[72]  M. Villacres,et al.  Internalization of iscom-borne antigens and presentation under MHC class I or class II restriction. , 1998, Cellular immunology.

[73]  Y. Ohtsuka,et al.  Phagocytosis of latex particles by leucocytes. I. Dependence of phagocytosis on the size and surface potential of particles. , 1986, Biomaterials.

[74]  Thomas Rades,et al.  Lipid based particulate formulations for the delivery of antigen , 2005, Immunology and cell biology.

[75]  H. Bluethmann,et al.  In interleukin‐4‐deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production , 1996, European journal of immunology.

[76]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[77]  A. Eggermont,et al.  Biodistribution and tumor localization of stealth liposomal tumor necrosis factor‐α in soft tissue sarcoma bearing rats , 1998, International journal of cancer.

[78]  G. Storm,et al.  Lymphatic Uptake and Biodistribution of Liposomes After Subcutaneous Injection: III. Influence of Surface Modification with Poly(ethyleneglycol) , 1997, Pharmaceutical Research.

[79]  I. Jones,et al.  A block in virus-like particle maturation following assembly of murine leukaemia virus in insect cells. , 2003, Virology.

[80]  D. Mahvi,et al.  Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I/IB study. , 2002, Human gene therapy.

[81]  R. Furneaux,et al.  Mannosylated liposomes as antigen delivery vehicles for targeting to dendritic cells , 2006, The Journal of pharmacy and pharmacology.

[82]  A. Maitra,et al.  Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. , 2002, International journal of pharmaceutics.

[83]  R. Sakakibara,et al.  Liposome oligomannose‐coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ cytotoxic T lymphocytes , 1998, FEBS letters.

[84]  Istvan Toth,et al.  Encapsulation of lipopeptides within liposomes: effect of number of lipid chains, chain length and method of liposome preparation. , 2005, International journal of pharmaceutics.

[85]  T. Rades,et al.  Immuno‐stimulating complexes prepared by ethanol injection , 2005, The Journal of pharmacy and pharmacology.

[86]  I. Barr,et al.  ISCOMs and other saponin based adjuvants. , 1998, Advanced drug delivery reviews.

[87]  J. Brewer,et al.  Interleukin‐18 plays a role in both the alum‐induced T helper 2 response and the T helper 1 response induced by alum‐adsorbed interleukin‐12 , 2003, Immunology.

[88]  M. Plebanski,et al.  Vaccines that facilitate antigen entry into dendritic cells , 2004, Immunology and cell biology.

[89]  J. Cleland.  Solvent Evaporation Processes for the Production of Controlled Release Biodegradable Microsphere Formulations for Therapeutics and Vaccines , 1998, Biotechnology progress.

[90]  R. Gupta,et al.  Adjuvant properties of aluminum and calcium compounds. , 1995, Pharmaceutical biotechnology.

[91]  J. Miyazaki,et al.  Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. , 1997, Journal of immunology.